M. Baltay

SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma

L. Macconaill, N. Lindeman, M. Nucci, 2018, Modern Pathology.

Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial.

Traci M. Blonquist, D. Neuberg, T. Graubert, 2019, The Lancet. Haematology.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

E. Winer, W. Barry, D. Dillon, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures

J. Aster, W. Wong, R. Hasserjian, 2019 .

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Lauren L. Ritterhouse, E. Winer, C. Hudis, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Characterization of Neuroendocrine Carcinomas of the Endometrium

L. Macconaill, N. Lindeman, M. Nucci, 2020, The American journal of surgical pathology.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).

C. Bloomfield, L. Garraway, Judit Jané-Valbuena, 2018, Blood advances.

Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures

J. Aster, W. Wong, R. Hasserjian, 2019, PloS one.